Compare Quest Diagnostics Inc (DGX) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Thomson Reuters Corp — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Thomson Reuters Corp trades at $91.74 (market cap $39.67B). The key difference: Thomson Reuters Corp is the larger of the two by market cap, and Thomson Reuters Corp pays the higher dividend (2.86%). Which is the better fit depends on your goals.
| DGX | TRI | |
|---|---|---|
Market Cap | $22.80B | $39.67B |
Sector | Health | Industrials |
52-Week High | $216.02 | $211.14 |
52-Week Low | $166.42 | $76.55 |
Enterprise Value | $28.82B | $41.62B |
Dividend Yield | 1.67% | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Thomson Reuters (TRI) trades at $94.29, up 5.18% today, showing strong momentum near resistance at $95. The stock maintains solid fundamentals with a 19.93% net margin and has beaten earnings estimates in two of the last three quarters. Recent developments include a joint venture with KKR and continued AI integration, positioning the company for growth in legal and professional markets.
The outlook is positive with a consensus price target of $129.96 implying 38% upside, supported by bullish analyst ratings (52% Buy). Key risks include execution of AI strategies and potential revenue pressures from market shifts. Institutional confidence remains high given stable cash flows and strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
